Nuformix (LON:NFX) chairman Dr Chris Blackwell speaks to Proactive following the release of its results to March 2020. He says the focus over the year has been towards the treatment of patients with fibrosis and the development of its anti-fibrotic candidate NXP002. Blackwell adds that he's excited about two new recent revenue generating collaborations they've agreed with Ebers Tech and VistaGen Therapeutics.
Nuformix PLC focused on licensing agreements and further fee-for-service work
